rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

INmune Bio Inc.

INMB · Nasdaq

Health CareBiotechnologyJust dropped outNeurotech

INMB stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 7.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
78 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders78+0 on the quarter
New · exited21 · 22
Reported value$6.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026706,424$1.2M+19,409+2.8%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026662,218$1.1M+391,901+145.0%
BlackRock, Inc.reduced · filed 7 Aug 2026311,613$508K-882,499−73.9%
RAYMOND JAMES FINANCIAL INCadded · filed 14 Aug 2026212,995$347K+9,750+4.8%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026190,215$310K-304,754−61.6%
GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 2026185,245$302K-46,341−20.0%
MILLENNIUM MANAGEMENT LLCnew · filed 14 Aug 2026159,559$260K+159,559
SUSQUEHANNA INTERNATIONAL GROUP, LLPreduced · filed 14 Aug 2026158,452$258K-35,939−18.5%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026134,232$219K+83,288+163.5%
UBS Group AGreduced · filed 13 Aug 2026110,413$180K-142,927−56.4%
31 Mar 2023 – 30 Jun 2026
295376Mar 23Dec 23Dec 24Sep 25Jun 26

News

Everyone who traded it

James Sapirstein Company insiderDirector · last 15 Sep 20260 · 0
Ronnie Duane Clark Company insiderDirector · last 15 Sep 20260 · 0
David J. Moss Company insiderChief Executive Officer · last 2 Jul 202610 · 6
Mark William Lowdell Company insiderChief Scientific Officer · last 2 Jul 20262 · 5
Scott Juda Company insiderDirector · last 2 Jul 20267 · 0
Cory Randall Ellspermann Company insiderCFO · last 1 Dec 20250 · 0
James Kelly Ganjei Company insiderDirector · last 1 Dec 20250 · 0
Marcia Allen Company insiderDirector · last 1 Dec 20250 · 0
Timothy J. Schroeder Company insiderDirector · last 1 Dec 20250 · 6
Raymond Joseph Tesi Company insiderPresident and CEO · last 5 Dec 20249 · 5
Edgardo Baracchini, Jr. Company insiderDirector · last 14 May 20240 · 0
Xencor Inc Company insider10% owner · last 3 Sep 20210 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-198%
Share count trendFY 2025 · to 30 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$24.8M
Free cash flowFY 2025 · to 31 Dec 2025−$23.6M

Analyst forecasts

No analyst forecasts yet.